476 related articles for article (PubMed ID: 9816118)
1. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients.
Chambers SK; Davis CA; Chambers JT; Schwartz PE; Lorber MI; Hschumacher RE
Clin Cancer Res; 1996 Oct; 2(10):1699-704. PubMed ID: 9816119
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Sabbatini P; Aghajanian C; Dizon D; Anderson S; Dupont J; Brown JV; Peters WA; Jacobs A; Mehdi A; Rivkin S; Eisenfeld AJ; Spriggs D
J Clin Oncol; 2004 Nov; 22(22):4523-31. PubMed ID: 15542803
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Morgan RJ; Synold TW; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow JH
Cancer Chemother Pharmacol; 2004 Oct; 54(4):283-9. PubMed ID: 15184995
[TBL] [Abstract][Full Text] [Related]
9. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
[TBL] [Abstract][Full Text] [Related]
16. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
18. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study.
Atmaca A; Al-Batran SE; Neumann A; Kolassa Y; Jäger D; Knuth A; Jäger E
Gynecol Oncol; 2009 Feb; 112(2):384-8. PubMed ID: 19059635
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
[TBL] [Abstract][Full Text] [Related]
20. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
